Group 1 - The article does not provide any specific company or industry analysis, focusing instead on the author's qualifications and disclosures [1][2][3]

Core Insights - CTS reported Q2 2025 results with non-GAAP EPS of $0.57 and GAAP revenue of $135.3 million, reflecting a year-over-year revenue increase of 3.8% from $130.2 million in Q2 2024 [1][2] - The adjusted gross margin improved by 2.9 percentage points to 38.7% compared to Q2 2024, indicating ongoing progress in margin expansion and profitability [1][2][5] - The company is focusing on diversification in industrial, medical, and aerospace/defense sectors to mitigate risks associated with transportation market fluctuations [4][7] Financial Performance - Non-GAAP free cash flow increased significantly from $15.0 million in Q2 2024 to $25.1 million in Q2 2025, showcasing strong cash generation capabilities [2][6] - Adjusted EBITDA margin rose to 23.0%, up 1.3 percentage points from the previous year, reflecting improved profitability metrics [2][5] - Revenue from the medical and aerospace/defense markets showed strong volume gains, while transportation revenue faced challenges due to softer demand in China and increased competition [7][8] Business Strategy - CTS has shifted its strategy to prioritize growth in industrial, medical, and aerospace/defense sectors, which helps offset risks from declining transportation sales [4] - The company emphasizes continuous innovation, disciplined cost management, and a strong pipeline of new program wins in targeted growth markets as key success factors [4] - Management is focused on M&A-driven growth and shareholder returns, with planned capital expenditures expected to be approximately 4% of sales for FY2025 [10] Outlook - CTS maintains its fiscal 2025 guidance, expecting GAAP net sales between $520 million and $550 million and non-GAAP adjusted diluted EPS of $2.20 to $2.35 [9] - Investors should monitor margin performance, customer concentration dilution, and the pace of end-market diversification, as these factors will be critical for future performance [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-4639 CTS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) F ...

Financial Data and Key Metrics Changes - The company reported sales of $135 million for Q2 2025, an increase of 4% from $130 million in Q2 2024 [4] - Adjusted EBITDA expanded by 250 basis points sequentially and 130 basis points year-over-year [2][19] - Adjusted diluted earnings were $0.57 per share, up approximately 30% from Q1 2025 and up 7% from the prior year [5][19] - The adjusted gross margin was 38.7%, an increase of 296 basis points compared to Q2 2024 [18] Business Line Data and Key Metrics Changes - Diversified end market sales increased by 13% year-over-year, accounting for 55% of overall company revenue [4][17] - Medical end market sales were up 8% compared to the same period in 2024, with therapeutic products demand increasing by approximately 60% year-over-year [6][7] - Aerospace and Defense sales rose by 34% year-over-year, with SideQuest revenues contributing $4.5 million [8][17] - Industrial market sales were up 5% sequentially and 6% year-over-year, with bookings up 22% from the prior year [9] Market Data and Key Metrics Changes - Transportation sales were €61 million in Q2 2025, down approximately 6% from the same period last year due to market dynamics in China [10] - The North American light vehicle market is expected to be in the 15 million unit range, while European production is forecasted at 16 million units [13][14] - China volumes are projected to be in the 30 million unit range, with electric vehicle penetration rates softening in some regions [14] Company Strategy and Development Direction - The company is focused on a diversification strategy to enhance growth in medical, industrial, aerospace, and defense markets [2][3] - The integration of the SideQuest business is progressing well, with expectations for stronger sales in the second half of 2025 [8][15] - The company aims to expand its customer base and range of applications in diversified end markets [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the impact of tariffs was minimal in Q2 2025, but they continue to monitor the situation closely [26] - There is cautious optimism regarding the transportation market, with expectations of a bottoming out in China [28] - The company maintains guidance for sales in the range of $520 million to $550 million and adjusted diluted EPS between $2.20 and $2.35 [16] Other Important Information - The company generated $28 million in operating cash flow in Q2 2025, compared to $20 million in Q2 2024 [20] - A total of $26 million has been returned to shareholders through dividends and share buybacks in 2025 [20] Q&A Session Summary Question: Insights on the medical market dynamics - Management indicated that while therapeutics are performing well, there is some softness in diagnostics due to capital spending in Asia and potential tariff impacts [24][25] Question: Impact of tariffs on the company - The impact of tariffs was described as nominal, with ongoing monitoring of the situation [26][27] Question: Transportation market outlook - Management expressed cautious optimism about the transportation market, noting mixed conditions across regions and potential bottoming out in China [28][29] Question: Integration of SideQuest and cost-saving measures - The integration of SideQuest is progressing well, with a strong pipeline of opportunities, and no significant cost-saving measures are currently being implemented [30][32] Question: Acquisition market outlook - The company is focused on advancing diversified end markets and sees potential opportunities for acquisitions within the next twelve months [53][54]

Financial Performance - Revenue reached $135 million, a 4% increase compared to the same period last year[9] - Adjusted Gross Margin improved by 296 bps to 38.7%[9, 36] - Adjusted Diluted EPS increased by 7% to $0.57[9, 36] - Operating cash flow generated was $28 million[12] End Markets - Diversified end markets (industrial, aerospace & defense, and medical) saw revenue increase by 13% year-over-year and accounted for 55% of total revenue[12, 39] - Medical sales in Q2 were $19 million, up 8% year-over-year[19] - Aerospace & Defense sales in Q2 were $21 million, up 34% year-over-year[19] - Industrial sales in Q2 were $34 million, up 6% year-over-year[27] - Transportation end market revenue decreased by (6)% year-over-year due to lower commercial vehicle sales and softness in China[12, 39] Bookings and Outlook - The company's total booked business in the transportation sector is approximately $1 billion at the end of Q2 2025[27] - FY 2025 revenue is projected to be between $520 million and $550 million[29] - FY 2025 Adjusted Diluted EPS is projected to be between $220 and $235[29]

Exhibit 99.1 July 24, 2025 FOR IMMEDIATE RELEASE CTS Announces Second Quarter 2025 Results Advancing Diversification and Profitability Lisle, Ill. - CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced second quarter 2025 results. "We delivered another quarter of double-digit sales growth in the diversified end markets and achieved solid profitability with adjusted EBITDA margin expanding 130 basis points. We a ...

LISLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE: CTS), a leading global designer and manufacturer of custom engineered solutions that “Sense, Connect and Move,” today announced second quarter 2025 results. “We delivered another quarter of double-digit sales growth in the diversified end markets and achieved solid profitability with adjusted EBITDA margin expanding 130 basis points. We also generated strong operating cash flow in the quarter,” said Kieran O’Sullivan, CEO of CTS Corporati ...

Core Viewpoint - CTS Corporation is set to release its second quarter 2025 earnings on July 24, 2025, at 8:00 a.m. (ET) [1] Group 1: Earnings Release Information - The earnings release for the second quarter 2025 will occur on July 24, 2025, at approximately 8:00 a.m. (ET) [1] - A conference call to discuss the results is scheduled for the same day at 10:00 a.m. (ET) [2] - Dial-in numbers for the conference call include +1-833-470-1428 (Toll-Free) and +1-404-975-4839 (Local) for U.S. callers [2] Group 2: Webcast and Archiving - A live audio webcast of the conference call will be available on the Investors section of the CTS Corporation website [3] - The webcast will be archived for one year for future access [3] Group 3: Company Overview - CTS Corporation is a leading designer and manufacturer of products that Sense, Connect, and Move [4] - The company produces sensors, actuators, and electronic components across North America, Europe, and Asia [4] - CTS serves various markets including aerospace/defense, industrial, medical, and transportation [4]

Company Announcement - CTS Corporation has appointed Mark Pacioni as Chief Legal & Administrative Officer and Corporate Secretary, effective July 1, 2025 [1] - Mark Pacioni previously served as Chief Legal Officer and Secretary of CareerBuilder, LLC and has held senior legal roles at Boeing, Molex, and Knowles [2] Leadership Insight - CTS Chairman and CEO, Kieran O'Sullivan, expressed confidence in Mark Pacioni's ability to contribute to the company's future success and global strategy [3] Company Overview - CTS is a leading designer and manufacturer of products that Sense, Connect, and Move, with operations in North America, Europe, and Asia [3] - The company provides engineered products to various markets including aerospace/defense, industrial, medical, telecommunications/IT, and transportation [3]

Company Overview - CTS is a designer and manufacturer of sensors, actuators, and electronic components with 15 manufacturing locations globally and approximately 3,200 employees[4] - In 2018, CTS achieved sales of $470 million[4] - The company's vision is to be a leading provider of sensing and motion devices, as well as connectivity components[12] Sales Breakdown (2018) - By Market: Transportation accounted for 64%, Industrial 18%, Medical 9%, Aero & Defense 5%, and Telecom & IT 4% of sales[5] - By Region: Americas contributed 54%, Asia 31%, and Europe 15% of sales[7] Financial Performance - The company's booked business was $1,866 million in Dec 2017 and is expected to ship $1,737 million in 2019[40] - Sales increased from $423 million in 2017 to $470 million in 2018[53] - Adjusted Earnings Per Share (EPS) increased from $123 in 2017 to $153 in 2018[53] - The company targets 10% annual growth through organic growth and acquisitions[47, 61] Capital Structure - The company's capital structure is composed of 88% equity and 12% debt[58] - The company targets operating cash flow of 12-15% of sales[60] - The company is targeting leverage between 10x and 25x EBITDA[60]